Teva Targets $113 Billion In Branded Sales With Dozens Of Pending Applications
This article was originally published in The Pink Sheet Daily
Executive Summary
The Israeli drug maker reports sales rose by 25 percent in 2009, and takes aim at a plethora of generic opportunities